“RO-Crate is a community effort to establish a lightweight approach to packaging research data with their metadata. It is based on schema.org annotations in JSON-LD, and aims to make best-practice in formal metadata description accessible and practical for use in a wider variety of situations, from an individual researcher working with a folder of data, to large data-intensive computational research environments….”
“We are pleased to announce the launch of our 500th gold open access journal, SSM – Qualitative Research in Health (SSMQR).
SSMQR is a new open access companion title to Social Science & Medicine and SSM – Population Health. The Journal welcomes interdisciplinary qualitative research – including both methodological and theoretical contributions – related to medical care, illness, disease, health, and wellbeing from across the globe….”
“This Collection of articles highlights all content published across the PLOS journals relating to the COVID-19 pandemic in 2019-20. PLOS is committed to disseminating research as quickly as possible, particularly in public health emergencies. All articles published in any PLOS journal are Open Access free of charge to all readers….”
“The Planning Committee is currently accepting proposals for presentations for the 2021 conference. Please consider submitting a proposal addressing any aspect of the scholarly communications field, librarianship, the serials industry, or serials management. Submissions by any member of the community including librarians, support staff, students, publishers, and vendors are welcome.
Possible topics could include:
* Scholarly communications and the roles of libraries, publishers, and vendors
* Diversity, Equity and Inclusion work within libraries
* Open access publishing …”
“Oxford University surprised and pleased advocates of overhauling the vaccine business in April by promising to donate the rights to its promising coronavirus vaccine to any drugmaker.
The idea was to provide medicines preventing or treating COVID-19 at a low cost or free of charge, the British university said. That made sense to people seeking change. The coronavirus was raging. Many agreed that traditional vaccine development, characterized by long lead times, manufacturing monopolies and weak investment, was broken….
A few weeks later, Oxford—urged on by the Bill & Melinda Gates Foundation—reversed course. It signed an exclusive vaccine deal with AstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of low prices—with the less-publicized potential for Oxford to eventually make millions from the deal and win plenty of prestige….”
“To me, Open Science means acceleration and democratization of scientific discoveries. It means increased transparency of the scientific enterprise and increased accountability of all stakeholders. Open Science maximizes the benefits of the scientific undertaking because it maximizes the sharing of knowledge….”
“The COVID-19 pandemic mobilized the global research and development community to embrace open science practices to accelerate the development of effective treatments. As described in this recent commentary by law professor Richard Gold, the COVID-19 crisis is an opportunity to move toward an open science drug discovery model to combat existing and future pandemics.
During the NIH Alzheimer’s Disease Research Summits in 2012, 2015, and 2018, we heard similar calls for open science from a large multi-stakeholder community in Alzheimer’s disease and related dementias (AD/ADRD) research. The collective input was the impetus for NIA to develop an array of new translational infrastructure programs, including AMP-AD and affiliated target discovery consortia (M2OVE-AD, Resilience-AD, and Psych-AD), and the MODEL-AD and TREAT-AD centers — all of which operate under open science principles — to rapidly deliver data, knowledge, and research tools necessary to overcome key barriers to developing effective therapies….”
Abstract: In April 2008, the National Institutes of Health (NIH) implemented the Public Access Policy (PAP), which mandated that the full text of NIH-supported articles be made freely available on PubMed Central – the NIH’s repository of biomedical research. This paper uses 600,000 NIH articles and a matched comparison sample to examine how the PAP impacted researcher access to the biomedical literature and publishing patterns in biomedicine. Though some estimates allow for large citation increases after the PAP, the most credible estimates suggest that the PAP had a relatively modest effect on citations, which is consistent with most researchers having widespread access to the biomedical literature prior to the PAP, leaving little room to increase access. I also find that NIH articles are more likely to be published in traditional subscription-based journals (as opposed to ‘open access’ journals) after the PAP. This indicates that any discrimination the PAP induced, by subscription-based journals against NIH articles, was offset by other factors – possibly the decisions of editors and submission behaviour of authors.
Abstract: There are few pharmacological therapeutics available for spinal cord injury despite years of preclinical and clinical research. This brief editorial discusses some of the shortcomings of translational research efforts. In addition, we comment on our previous experiences with data curation and highlight evolving efforts by the spinal cord injury research community to improve prospects for future therapeutic development, especially pertaining to preclinical data sharing through the Open Data Commons for Spinal Cord Injury (ODC-SCI).